Developmental and Reproductive Toxicity (DART) Studies Developmental and reproductive toxicity (DART) studies are crucial in identifying risks to human health and assessing the overall safety of chemicals and other substances Read more about Introducing vivoVerse’s Automated DART Assay: Scalable Developmental and Reproductive Toxicity Testing with C. elegans[…]
Developmental toxicity (DevTox) occurs when a chemical or substance disrupts an organism’s normal growth and developmental processes. The mechanisms underlying developmental toxicity may include structural malformations, molecular growth pathway interference, Read more about A Predictive NAM for Developmental Toxicity Testing: An Automated, Repeatable DevTox Assay Using Microfluidics and Machine Learning-Based Approaches[…]
How Dietary and Pharmacological Interventions Can Slow Progression of Neurodegenerative Diseases Protein homeostasis, or proteostasis, is essential for maintaining cellular function by ensuring proper protein folding, trafficking, and degradation. Disruption Read more about Unlocking the Mysteries of Protein Aggregation: Insights from C. elegans[…]
Caenorhabditis elegans (C. elegans), a tiny transparent roundworm, has become one of the most widely used model organisms in scientific research. First introduced to the laboratory by Sydney Brenner Read more about Why C. elegans Is a Powerful Model Organism in Biomedical Research[…]
On April 10, 2025, the FDA announced a major policy shift: creating a roadmap outlining a strategic approach to reduce animal testing in preclinical safety studies. This transition prioritizes New Read more about The FDA’s Shift from Animal Testing: Role of Small Model Organisms as NAMs[…]
Austin, TX — vivoVerse is proud to announce the publication of groundbreaking research that sets a new benchmark for developmental toxicity (DevTox) testing. This study highlights the transformative potential of Read more about vivoVerse revolutionizes developmental toxicity testing with AI-assisted high-throughput C. elegans image analysis[…]
The 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA, a small non-coding RNA molecule that plays a crucial Read more about C. elegans scientists awarded 2014 Nobel Prize in Medicine for their pioneering work discovering microRNA[…]
The vivoVerse team recently attended the 2023 Society of Toxicology (SOT) Annual Meeting. It was a great time networking with people in the toxicology and safety testing industry. At ToxExpo, Read more about Meeting report: A successful and enjoyable time at SOT2023 in Nashville for vivoVerse[…]
Toxicology testing (often called “safety testing” or “product safety testing”) is an essential component of many industries, including the chemical industry, pharmaceuticals, and environmental science. It involves the evaluation of Read more about C. elegans as a Model for Rapid, Cost-Effective Toxicology Assessments[…]
Dr. Sudip Mondal has a Ph.D. in Physics and several years of postdoctoral research experience in neuroscience and microfluidics-based screening tools. He has developed several technologies that have translated to the market. One of his recent works at The University of Texas at Austin involved a high-throughput screening platform with C. elegans model systems, which is commercialized by vivoVerse. As a Director of Science, Sudip is responsible for developing new technologies and innovative assays to increase the vivoVerse product & service portfolio.
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC, now vivoVerse. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at vivoVerse, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben-Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben-Yakar began the research that has culminated in the launch of vivoVerse (formerly Newormics)